Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13228087 | 0.88 | CES2 (0.47) | CES2MAPTNPSR1TAS1R3TAS1R1 | |
| SCHEMBL3798068 | 0.82 | CA12 (0.53) | PTGS2 | |
| SCHEMBL3796888 | 0.82 | CA12 (0.44) | CCR5MAPTKCNH2PTGS2 | |
| SCHEMBL30836057 | 0.82 | CES2 (0.49) | CES2MAPTNPSR1 | |
| SCHEMBL1043810 | 0.82 | CES2 (0.49) | CES2MAPTNPSR1 | |
| SCHEMBL13261837 | 0.81 | CES2 (0.41) | CES2MAPTNPSR1 | |
| SCHEMBL3797363 | 0.80 | PTGS2 (0.45) | CES2CCR5PTGS2 | |
| SCHEMBL3796823 | 0.79 | GAA (0.40) | — | |
| SCHEMBL3795486 | 0.79 | GAA (0.48) | KCNH2PTGS2 | |
| SCHEMBL11432112 | 0.79 | EPHX1 (0.52) | CES2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781592-B2 | Thione derivative, method for the preparation thereof, and pharmaceutical composition containing the same | CJ CHEILJEDANG CORPORATION (KR) | 2010-08-24 | — | — | US | disclosed |
| US-20080090875-A1 | Thione Derivative, Method For The Preparation Thereof, And Pharmaceutical Composition Containing The Same | CJC CORPORATION (KR) | 2008-04-17 | — | — | US | disclosed |
| WO-2005051941-A1 | THIONE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CJ CORPORATION (KR) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090875-A1 | Thione Derivative, Method For The Preparation Thereof, And Pharmaceutical Composition Containing The Same | TPMT, TST, CYP3A5 | CES2 1617/4885CCR5 3533/4885MAPT 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.